The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...
Many of us are familiar with the story of The Frog Prince, where a princess kisses a frog, and to her surprise, it transforms ...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report) and keeping the ...
On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approval ・Alignment with FDA ...
JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on OPT stock, giving a Buy rating on September 12. Debanjana ...
Transforming colleges into true incubators of adulthood, helping students not just to learn, but to grow into capable, resilient and self-aware individuals.
Changes affecting the approval of medical devices in Canada are coming. Health Canada has released a notice on Proposed Changes to the Guidance ...
In its latest warning letter, FDA raised concern that the company was still producing eye drops with amniotic fluid, even ...
From zero cost to the lack of limitations, the Linux operating system and open-source software may be worth looking into for ...
Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes ...
Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback